These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22290205)

  • 1. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report.
    Imboden C; Hatzinger M
    Pharmacopsychiatry; 2012 Jun; 45(4):162-3. PubMed ID: 22290205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature.
    Štuhec M
    Wien Klin Wochenschr; 2015 Sep; 127(17-18):703-6. PubMed ID: 25576334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
    Chang CC; Tzeng NS; Yeh CB; Kuo TBJ; Huang SY; Chang HA
    World J Biol Psychiatry; 2018 Aug; 19(5):368-378. PubMed ID: 28281386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [If the general practitioner has to decide: what is the evidence for the selection of antidepressants?].
    Staudigl L; Becker T; Kösters M
    Dtsch Med Wochenschr; 2014 Aug; 139(34-35):1727-30. PubMed ID: 25116024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine.
    Strawn JR; Whitsel R; Nandagopal JJ; Delbello MP
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):91-2. PubMed ID: 21309700
    [No Abstract]   [Full Text] [Related]  

  • 8. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
    Kennedy SH; Rizvi S; Fulton K; Rasmussen J
    J Clin Psychopharmacol; 2008 Jun; 28(3):329-33. PubMed ID: 18480691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine-induced hepatotoxicity.
    Štuhec M
    Wien Klin Wochenschr; 2013 Apr; 125(7-8):225-6. PubMed ID: 23519541
    [No Abstract]   [Full Text] [Related]  

  • 10. Duloxetine-induced life-threatening long QT syndrome.
    Štuhec M
    Wien Klin Wochenschr; 2013 Mar; 125(5-6):165-6. PubMed ID: 23440523
    [No Abstract]   [Full Text] [Related]  

  • 11. [Early effects of antidepressants].
    Llorca PM
    Encephale; 2012 Dec; 38 Suppl 2():S49-53. PubMed ID: 23279958
    [No Abstract]   [Full Text] [Related]  

  • 12. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
    Tomita T; Yasui-Furukori N; Kaneko S
    Clin Neuropharmacol; 2013; 36(5):175-6. PubMed ID: 24045610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
    Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
    J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Acute Problem Gambling Associated With Agomelatine.
    Menon R; Cribb L; Sarris J; Ng CH
    J Clin Psychopharmacol; 2018 Apr; 38(2):153-155. PubMed ID: 29432330
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
    Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report.
    Chen PY; Lin PY; Tien SC; Chang YY; Lee Y
    Gen Hosp Psychiatry; 2010; 32(6):646.e9-646.e11. PubMed ID: 21112461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.